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respectively, with a median survival time, calculated from 
the date of metastasis and last follow-up or death, of 29.8 
months. 
 
Conclusion: These data suggest that stereotactic ablative 
radiotherapy (SABR) is a safe, non-invasive and effective 
option in the treatment of liver metastases. 
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Purpose or Objective: The aim of this study was to 
investigate the outcome and prognostic factors for patients 
with locally advanced gastric cancer (LAGC) treated with 
adyuvant radiochemotherapy, according Macdonald scheme. 
 
Material and Methods: Between May 2004 and October 2014, 
a total of 106 patients, 70 men and 36 women, with locally 
advanced gastric cancer were treated in the University 
Hospital 12 de Octubre, Spain. The mean age was 57 years 
.The mean follow-up was 96.48 months. The most common 
tumor location was antrum (29.25%). The majority of tumors 
were T3 (52.83%) or T4 (22.64 %) and 86.79 % had nodal 
metastases, with an average of 8.24 nodes involved. 
Predominant histological subtype was diffuse (43.4%) and 
poorly differentiated (grade 3, 50%). Complete resection (R0) 
was achieved 84.91%, whereas microscopic residual disease 
(R1) was found in 13.21%. Survival was calculated by Kaplan-
Meier and method and differences were assessed by the Log-
rank test. Multivariate analysis was used Cox proportional 
hazards regression model. 
 
Results: A total of 50 (47.16 %) patients relapsed; 16 (15.09%) 
locoregional, 13 (12.26%) peritoneal, 18 (16.98%) distant 
metastases and 3 (2.83%) unknown. The overall survival (OS), 
disease-free survival ( DFS), locoregional failure-free survival 
(LFS) rates to three years were 48.75%, 46.27% and 76.72% 
and to five years were 32.11%, 38.78%, 69.67% respectively. 
In univariate analysis, T stage (T1-T2), N negative stage and 
R0 resection were associated with better survival (p<0.05) for 
OS and only N negative stage for DFS and LFS. In the 
multivariate analysis indentified only R0 resection as an 
independent predictor of better survival (p<0.05) for OS and 
DFS. 
 
Conclusion: In this study, the prognostic factors associated 
with better survival in patients with LAGC treated with 
adyuvant radiochemotherapy were: T stage (T1-T2), N 
negative stage and R0 resection ( p< 0.05). Complete R0 
resection also can be considered as independent prognostic 
factor of better survival (p<0.05) 
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Purpose or Objective: Activation of coagulation and 
fibrinolysis are found among gastric cancer patients. The 
ones with non-metastatic gastric cancer are at risk for 
thrombotic events due to the combined increase in fibrinogen 
plasma levels and thrombin formation. It could be associated 
with a higher risk of local invasion and might be important 
poor predictive and prognostic factor. In our study, we 
sought the associations between blood parameters and 
outcome 
 
Material and Methods: The study examined eighty-nine 
patients with biopsy-proven, operable gastric 
adenocarcinoma, with no evidence of distant metastases. 
Pre-operative fibrinogen, PT, APTT and INR levels were 
measured before surgery . Complete blood count were also 
collected before initiation of therapy . All patients 
underwent surgery as a primary treatment. The survival 
function was computed using Kaplan-Meier method. The 
overall survival (OS), Diseases- free survival (DFS), time to 
distant metastases (DM) and locoregional control (LRC) were 
calculated from the date of surgery. Multivariate analyses 
and characteristic (ROC) have been done. 
 
Results: In Multivariate Cox analysis higher level of WBC was 
associated with worse local control (p=0,0024), and shorter 
overall survival (p=0,0035). Shorter Prothrombin Time was 
correlated with better overall survival (p=0,0280). Higher 
Fibrinogen level has caused better local control (p=0,0280). 
No other correlation between DFS, LRC, DM and OS and other 
blood parameters were observed in multivariate analyses.  
 
Conclusion: The level of White Blood Cells, Fibrinogen and 
Prothrombin Time were found to be useful prognostic factor 
which influenced overall survival and local control. However, 
further prospective investigations are necessary to assess the 
predictive value of those factors. 
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Purpose or Objective: To evaluate the feasibility, efficacy 
and toxicity of robotic SBRT for the treatment of 
unresectable hepatic oligometastases. 
 
Material and Methods: Between 09/2010 and 01/2013, 15 
consecutive patients (12 female, 3 male, median age at 
treatment: 70.5, range: 57-85 years) with up to 3 
synchronous or metachronous hepatic oligometastases were 
referred for Cyberknife treatment (Accuray Incorporated, 
Sunnyvale, CA) at our center. In order to enable tumor 
tracking, gold fiducial markers were inserted around the 
lesion 2 weeks prior to each treatment. The treatment was 
delivered using the Synchrony Respiratory Tracking System to 
continuously track fiducial position and adjust for respiratory 
motion during treatment. Treatment planning was performed 
using the Multiplan TPS (v4.6, Accuray) with Raytracing 
algorithm, and was retrospectively recalculated using a 
Monte Carlo dose calculation algorithm (v5.1). The primary 
endpoint of this study was local control (LC), assessed with 
either contrast enhanced spiral CT or MRI. Secondary 
endpoints were liver and distant progression free-survival 
(liverPFS and DFS), overall survival (OS) and treatment 
toxicity, evaluated using the Common Terminology Criteria 
for Adverse Events v4.0. (Institute NC, NIH publication 2009). 
Statistical analysis was performed using R software (3.1.1, R 
Development Core Team 2010). 
 
Results: A total of 20 metastatic lesions were treated from 
primary colorectal (7), breast (7), unknown primary (3), 
melanoma (2) and stomach (1) cancer. The mean GTV and 
PTV volumes were 23.8cc (Standard deviation (SD):23) and 
74.5cc (SD:45.3) respectively. All treatments were delivered 
3x/week in a median three fractions (range: 3-6) to a median 
dose of 45 Gy (range: 30-45), prescribed to the 80% isodose 
line. This corresponds to an equivalent 2-Gy dose of 93.75Gy, 
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when considering a α/β ratio of 10. The mean GTV and PTV 
D98% and D50% were 41.6Gy (SD:7.7) and 46.5Gy (SD:6.8) 
,39.3Gy (SD:7) and 46.1Gy (SD:6.6) respectively. Each 
treatment was delivered by an average of 158 beams. All 
dose constraint parameters proposed by Timmerman were 
respected (Semin.Radiat.Oncol.2008). Furthermore, the 
average difference between the Raytracing and the Monte 
Carlo algorithm was 0.43% on these values. At a median 
follow up of 30.9 months (range: 5.7-50.3), the 1 and 2-year 
LC rates remained stable at 83.5%.The 1 and 2-year liver PFS 
and the DFS rates were 57.1%, 46.1% and 75.5%, 64.4% 
respectively. The 2 year OS was 60.6% (Figure 1). No acute 
grade 2 toxicities were observed. Three patients reported 
late grade 2 gastro-intestinal toxicities. No late grade 3 nor 4 
toxicities were reported. 
 
 
 
Conclusion: Robotic SBRT is feasible, safe and very well 
tolerated for the treatment of hepatic oligometastases. Our 
outcome results compare favorably from previous published 
studies of SBRT. It could represent a valid treatment option 
in the multimodality treatment of unresectable hepatic 
oligometastases. 
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Purpose or Objective: Patients with locally advanced 
gallbladder cancer (LAGC) have a dismal prognosis. We 
investigated outcomes and risk factors for overall survival 
(OS) in patients treated with radical surgery and adyuvant 
chemoradiotherapy (CRT). 
 
Material and Methods: A total of 212 patients with LAGC 
[⩾cT3 59% and/or cN+ 52%) were studied. For survival 
outcomes potential associations were assessed in univariate 
and multivariate analyses using the Cox proportional hazards 
model. We constructed a risk scoring system in which points 
were assigned to each risk factor by dividing each ß 
coefficient in the final model by the lowest ß coefficient and 
rounding to the nearest integer. 
 
Results: Median follow-up was 46.2 months (2-235). Five-year 
OS for the entire cohort was 50.2%. In multivariate analysis 
higher pT stage [HR 1.73, p = 0.01], R1 resection [HR 5.06, p 
< 0.01], and number of surgical procedures [HR 1.41, p = 
0.05] were associated with an increased risk of death. A risk 
model was generated to determine a prognostic index for 
individual patients with LAGC. 
 
Conclusion: Overall results after multimodality treatment of 
LAGC are promising. Classification of risk factors for death 
has contributed to propose a prognostic index that could 
allow us to guide risk-adapted tailored treatment 
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Purpose or Objective: To retrospectively review the 
treatment outcome of esophageal cancer in our hospital, and 
compare the radiotherapy efficacy and toxicity of helical 
tomotherapy with step-and-shoot Intensity Modulation 
Radiation Therapy (IMRT). 
 
Material and Methods: Between 2007 and 2012, 108 
consecutive patients with locally advanced esophageal 
cancer, cT2-4N0-3M0-1, received neoadjuvant concurrent 
chemoradiotherapy (CCRT) followed by esophagectomy or 
definitive CCRT treatment course respectively. The 
radiotherapy was delivered with helical tomotherapy in 56 
patients, and with conventional IMRT in other 52 patients. 
We had evaluated outcomes with radiation dose, overall 
survival rate (OS), disease-free survival rate (DFS), and 
toxicity of radiation pneumonitis. 
 
Results: The median follow-up duration was 16 months. The 
median time of overall survival among all patients was 15 
months. The treatment modality with neoadjuvant CCRT 
followed by esophagectomy had favorable OS (47.6% : 
10.4%，p = 0.014), DFS (42.9% : 23.9%，p = 0.013), and local 
recurrence (33.3% : 50.7%，p = 0.574) comparing with 
definitive CCRT. No significant difference outcome of OS was 
found between tomotherapy and conventional IMRT. The 
patients using tomotherapy had less incidence and severity of 
radiation pneumonitis (only one patient with less than grade 
3 radiation pneumonitis in tomotherapy group; 5 patients < 
grade 3 and 2 patients > grade 3 radiation pneumonitis in 
conventional IMRT group). 
 
Conclusion: In our study, the treatment outcomes of 
neoadjuvant CCRT followed by esophagectomy for esophageal 
cancer are better in OS, DFS, and local control than 
definitive CCRT. Tomotherapy may reduce lung dose, and 
probably reduce incidence and severity of radiation 
pneumonitis when compared with conventional IMRT. 
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Purpose or Objective: To evaluate the feasibility and 
efficacy of Stereotactic Ablative Body Radiotherapy (SABR) in 
the treatment of liver metastases from radioresistant primary 
tumors. 
 
Material and Methods: Patients with inoperable liver 
metastases from renal cancers, melanoma and sarcomas, not 
amenable to other locoregional therapies, treated with SABR 
were included in this retrospective study. Inclusion criteria 
were: Karnofsky Performance Status of 70; no evidence of 
progressive or untreated gross disease outside the liver; 
maximum tumor diameter less than 6 cm; no more than 3 
liver lesions; normal liver volume greater than 1000 cm3; 
adequate liver function. Dose prescription ranged from 75 to 
50.26Gy in 3 consecutive fractions, delivered with RapidArc 
VMAT, with 10MV FFF photons. Local control was defined 
according to RECIST criteria.Toxicity was classified according 
to the Common Toxicity Criteria (CTC) version 3.0. 
 
Results: From April 2010 to October 2015, 20 patients were 
treated with SABR for a total number of 24 lesions. Median 
follow-up was 21 (range 6–58) months. In field progression 
was observed in 1 patient for a total of 2 lesions. One and 2 
